Effect of lncRNA ANRIL silencing on anoikis and cell cycle in human glioma via microRNA-203a
Authors Dai W, Tian C, Jin S
Received 31 March 2018
Accepted for publication 1 June 2018
Published 23 August 2018 Volume 2018:11 Pages 5103—5109
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Dr Samir Farghaly
Weiying Dai,* Chao Tian,* Song Jin
Department of Radiology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin 300350, People’s Republic of China
*These authors contributed equally to this work
Background: Glioma is a deadly nervous system tumor with a poor prognosis. Although there have been many efforts to overcome glioma, the molecular mechanism of its pathogenesis remains unclear.
Methods: We used human glioma U251 cells silenced for the oncogenic lncRNA ANRIL or overexpressing the anti-oncogene miR-203a to examine the role of lncRNA ANRIL silencing on anoikis and cell cycle arrest by flow cytometry. Meanwhile, the activity of caspase-3/8/9 was measured by fluorometric assay, the expression of tumor-related genes and activity of AKT signaling pathway was measured by Western blotting, real-time PCR, and dual luciferase reporter gene assay.
Results: lncRNA ANRIL was positively correlated with glioma grade and negatively correlated with miR-203a. lncRNA ANRIL silencing could induce anoikis and cell cycle arrest in G0/G1 phase, while regulating the activity of caspase-3/8/9 and the AKT signaling pathway, and the expression of tumor-related genes in the U251 cell line. miR-203a mimics could partially reverse these functions.
Conclusion: We consider that lncRNA ANRIL is a potential therapeutic and diagnostic target for glioma, and miR-203a plays an important role in the biological function of lncRNA ANRIL in glioma.
Keywords: glioma, long non-coding RNA, anoikis, cell cycle, lncRNA ANRIL, microRNA-203a
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]